LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice

European Journal of Heart Failure

Volumn 18, Issue 4, 2016, Pages 386-393

  Suematsu, Yasunori ^a   Miura, Shin Ichiro ^a   Goto, Masaki ^a   Matsuo, Yoshino ^a   Arimura, Tadaaki ^a   Kuwano, Takashi ^a   Imaizumi, Satoshi ^a   Iwata, Atsushi ^a   Yahiro, Eiji ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiac function; Diabetes mellitus; Fibrosis; Heart failure with reduced ejection fraction; LCZ696

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; ENKEPHALINASE INHIBITOR; MESSENGER RNA; SACUBITRIL PLUS VALSARTAN; TRANSFORMING GROWTH FACTOR BETA; VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; DRUG COMBINATION; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GENE EXPRESSION; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RATIO OF HEART WEIGHT TO BODY WEIGHT; REPERFUSION INJURY; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARDIAC MUSCLE; DRUG COMBINATION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GENETICS; HEART; HEART STROKE VOLUME; HEART VENTRICLE; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANIMALS; ATRIAL NATRIURETIC FACTOR; DIABETES MELLITUS, EXPERIMENTAL; DRUG COMBINATIONS; FIBROSIS; HEART; HEART FAILURE; HEART VENTRICLES; MALE; MICE; MICE, INBRED C57BL; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NEPRILYSIN; RNA, MESSENGER; STROKE VOLUME; TETRAZOLES; TRANSFORMING GROWTH FACTOR BETA;

EID: 84953931431     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.474     Document Type: Article

References (31)

1. Voors AA, Dorhout B, van der Meer P,. The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure. Expert Opin Investig Drugs 2013; 22: 1041-1047.
2. Gardner DG, Chen S, Glenn DJ, Grigsby CL,. Molecular biology of the natriuretic peptide system: implications for physiology and hypertension. Hypertension 2007; 49: 419-426.
3. Song W, Wang H, Wu Q,. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 2015; 569: 1-6.
4. McDowell G, Coutie W, Shaw C, Buchanan KD, Struthers AD, Nicholls DP,. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol 1997; 43: 329-332.
5. Fryer RM, Segreti J, Banfor PN, Widomski DL, Backes BJ, Lin CW, Ballaron SJ, Cox BF, Trevillyan JM, Reinhart GA, von Geldern TW,. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008; 153: 947-955.
6. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ,; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387-1395.
7. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD,. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36: 1990-1997.
8. Zijlstra F, Hoorntje JC, de Boer MJ, Reiffers S, Miedema K, Ottervanger JP, van't Hof AW, Suryapranata H,. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999; 341: 1413-1419.
9. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, Fox KA, Rajwani A, BaigW, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, Sapsford RJ, Wheatcroft SB, Witte KK, Kearney MT,. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circulation 2011; 4: 396-403.
10. Garg R, Yusuf S,. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
11. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
12. Golwala HB, Thadani U, Liang L, Stavrakis S, Butler J, Yancy CW, Bhatt DL, Hernandez AF, Fonarow GC,. Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. J Am Heart Assoc 2013; 2:e000214.
13. Watson CJ, Gupta SK, O'Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T,. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail 2015; 17: 405-415.
14. Okawa H, Horimoto H, Mieno S, Nomura Y, Nakahara K, Yoshida M, Asada K, Sasaki S,. Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotection through a nitric oxide-dependent mechanism. J Cardiol 2002; 39: 299-304.
15. Sezai A, Hata M, Wakui S, Niino T, Takayama T, Hirayama A, Saito S, Minami K,. Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome. Circ J 2007; 71: 1401-1407.
16. Han J, Park SJ, Thu VT, Lee SR, Long le T, Kim HK, Kim N, Park SW, Jeon ES, Kim EJ, Yoon CH, Cho GY, Choi DJ,. Effects of the novel angiotensin II receptor type I antagonist, fimasartan on myocardial ischemia/reperfusion injury. Int J Cardiol 2013; 168: 2851-2859.
17. Rubler S, Dlugash J, Yuceoglu Y. Z, Kumral T, Branwood A. W, Grishman, A,. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972; 30: 595-602.
18. King H, Aubert RE, Herman WH,. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
19. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ,. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001; 38: 421-428.
20. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR,;, BEST Investigators,. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol 2003; 42: 914-922.
21. Booth GL, Kapral MK, Fung K, Tu JV,. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006; 368: 29-36.
22. Dongqing Y, Yidan X, Hui H, Xiaoyi L, Xi C, Ping X, Songtao Y, Weiwei Z, Xiaojun L, Qinghuai L,. Edaravone protect against retinal damage in streptozotocin-induced diabetic mice. PLoS One 2014; 9:e99219.
23. Gu J, Noe A, Chandra P, Al-Fayoumi S, Ligueros-Saylan M, Sarangapani R, Maahs S, Ksander G, Rigel DF, Jeng AY, Lin TH, Zheng W, Dole WP,. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010: 50; 401-414.
24. Pacher P, Nagayama T, Mukhopadhyay P, Batkai S, Kass DA,. Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc 2008; 3: 1422-1434.
25. Von Lueder TG, Wang BH, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H,. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. Circ Heart Fail 2015; 8: 71-78.
26. Bai HY, Mogi M, Nakaoka H, Kan-No H, Tsukuda K, Chisaka T, Wang XL, Kukida M, Shan BS, Yamauchi T, Higaki A, Iwanami J, Horiuchi M,. Pre-treatment with LCZ696, an orally active angiotensin receptor neprilysin inhibitor, prevents ischemic brain damage. Eur J Pharmacol 2015; 762: 293-298.
27. Giannetta E, Isidori AM, Galea N, Carbone I, Mandosi E, Vizza CD, Naro F, Morano S, Fedele F, Lenzi A,. Chronic inhibition of cGMP phosphodiesterase 5A improves diabetic cardiomyopathy a randomized, controlled clinical trial using magnetic resonance imaging with myocardial tagging. Circulation 2012; 125: 2323-2333.
28. Takahashi N, Saito Y, Kuwahara K, Harada M, Kishimoto I, Ogawa Y, Kawakami R, Nakagawa Y, Nakanishi M, Nakao K,. Angiotensin II-induced ventricular hypertrophy and extracellular signal-regulated kinase activation are suppressed in mice overexpressing brain natriuretic peptide in circulation. Hypertens Res 2003; 26: 847-853.
29. Kapoun AM, Liang F, O'Young G, DammDL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA,. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 2004; 94: 453-461.
30. Tsuneyoshi H, Nishina T, Nomoto T, Kanemitsu H, Kawakami R, Unimonh O, Nishimura K, Komeda M,. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 2004; 110: 174-179.
31. Kishimoto I, Rossi K, Garbers DL,. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001; 98: 2703-2706.